Categories
Tag: ctDNA
Postdoc/assistant professor in molecular biology and bioinformatics: Structural variations associated to circular DNA in cancer – University of Copenhagen – job portal
Job Portal Postdoc/assistant professor in molecular biology and bioinformatics: Structural variations associated to circular DNA in cancer Department of Biology, Faculty of Science at University of Copenhagen is offering a position in molecular biology and bioinformatics for a Postdoc/assistant professor for the analysis of extrachromosomal circular DNA in 1 April…
Improving sensitivity and success of liquid c
Intravenous nanoparticle priming agents given hours before a blood draw greatly increase the sensitivity to liquid biopsies for detecting cancer, according to a preclinical study in mice. In these animals, the approach increased the sensitivity for detection of small tumors from 10% to 75%. “Just as iodinated and gadolinium contrast…
cfDNA Standards For Molecular Testing
Multiplexed ctDNA fragments (~150bp) mixed with nucleosomally fragmented wildtype cfDNA background in human plasma. The cell-derived ctDNA fragments are generated by Anchor’s unique multiplexed gene-editing method and are nucleosomally fragmented to around 150bp. The cell-derived variants are suitable for both the amplicon-based and capture-based methods. The synthetic ctDNA fragments are…
ICR study increases understanding of advanced breast cancer complication
Researchers at the Institute of Cancer Research (ICR) have increased the understanding of a complication of advanced breast cancer which could help to develop effective treatments. Researchers implanted patients’ breast cancer leptomeningeal metastasis (BCLM) cells into mice to create models of the disease to advance research into the secondary form…
How MRD Testing Can Help
MRD testing is incredibly valuable in informing clinical decision-making in the treatment of lymphoid malignancies, and its adoption by all oncologists is crucial in the era of precision medicine. During my 10 plus years of practicing medicine, I have seen the blood cancer treatment landscape transform, as the development of…
[Analysis of the feasibility and prognostic value of circulating tumor DNA monitoring in detecting gene mutations in patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy]
Objective: To explore the prognostic value of circulating tumor DNA (ctDNA) testing in patients with refractory/relapsed diffuse large B-cell lymphoma (R/R DLBCL) undergoing chimeric antigen receptor T-cell (CAR-T) therapy, and to guide the prevention and subsequent treatment of CAR-T-cell therapy failure. Methods: In this study, 48 patients with R/R DLBCL…
Bioinformatics Scientist, San Jose, California
Our company is a Silicon Valley based biotech startup focusing on non-invasive diagnostics (liquid biopsy) to facilitate early detection of cancer. We are developing systems that will provide the most sensitive, accurate, and robust NGS-based ctDNA mutation detection. We are looking for a highly motivated Scientist to join our Bioinformatics…
Precision Medicine: A New Era in Cancer Therapy
Precision medicine can offer improved clinical outcomes by assessing the unique characteristics of tumors, such as their likelihood of developing resistance to chemotherapy. Stay up to date on the latest science with Brush Up Summaries. Precision Medicine in Cancer Precision medicine for cancer treatment involves tailoring treatments to an individual…
[2024-2031] Cell-Free DNA (cfDNA) Testing Market Size, Share Regional Report
Most recent research on Cell-Free DNA (cfDNA) Testing Market 2024 with 103 Pages Report and enhanced with self-explanatory tables, pie charts, and graphs in smart format. In the study, you will discover new, advanced market sizes, the newest trends, CAGR status, drivers, developing plans, restraints, trending technologies, and opportunities created…
MD Anderson Research Highlights for December
HOUSTON ― The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back. Recent developments at…
New understanding of devastating type of breast cancer spread could lead to better treatments
Image: Proliferating cells in a breast cancer tumour organoid. Credit: ICR A new study has increased the understanding of an increasingly common complication of advanced breast cancer. Using a novel approach, researchers have uncovered details of secondary breast cancer in the brain and spinal cord that may help with developing…
Increasing Widespread Accessibility of Molecular Testing for Oncology Research
Advancements in cancer diagnostics and monitoring have revolutionized the way we understand and treat this complex disease. The advent of molecular technologies for analyzing nucleic acids has made it possible to detect, analyze and monitor cancer more precisely and sensitively than ever before. Furthermore, it has made noninvasive liquid biopsy…
Tafasitamab Quadruplet Determined Safe, Feasible in Newly Diagnosed DLBCL
Lymphoma cells: © Dr_Microbe – stock.adobe.com A targeted combination regimen of lenalidomide (Revlimid), tafasitamab-cxix (Monjuvi), rituximab (Rituxan), and acalabrutinib (LTRA) seemed to be safe and effective in the first line as treatment for patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL), with the addition of cyclophosphamide, doxorubicin, vincristine, and…
Tafasitamab Quadruplet Appears Safe, Feasible in Newly Diagnosed DLBCL
This study inspired investigators to ask whether better outcomes could be achieved via targeted therapies. To do this, investigators chose to examine acalabrutinib—which demonstrated more selectivity and appeared more safe/efficacious with rituximab and CHOP (R-CHOP)—and tafasitamab—which has been successfully combined with lenalidomide and yields high ORRs and CR rates in…
Tafasitamab Quadruplet Shows Efficacy in Newly Diagnosed DLBCL
Jason Westin, MD, MS, FACP The use of tafasitamab-cxix (Monjuvi), lenalidomide (Revlimid), rituximab (Rituxan), and acalabrutinib (Calquence; LTRA) in the first-line setting induced high responses in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL), with responders deriving benefit from subsequent treatment with cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP), according…
Construction of a risk stratification model integrating ctDNA to predict response and survival in neoadjuvant-treated breast cancer | BMC Medicine
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. Article PubMed Google Scholar Giaquinto AN, Sung H, Miller KD, Kramer JL, Newman LA,…
Liquid Biopsy Uses ctDNA to Predict Recurrence of Hodgkin Lymphoma
A Stanford Medicine-led, international study of hundreds of samples from patients with classic Hodgkin lymphoma (cHL) has shown that levels of tumor DNA circulating in the blood can identify those individuals who are responding well to treatment and those who are likely to experience a disease recurrence. The study results suggest…
Odronextamab Continues to Appear Safe, Effective in Patients With R/R DLBCL
Treatment with odronextamab (REGN1979) led to an objective response rate (ORR) of 52%, with encouraging progression-free (PFS) and overall survival (OS) among complete responders in a cohort of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), according to a final analysis of the phase 2 ELM-2 trial (NCT03888105) presented at…
Pilot study uses circulating tumor DNA to reliably predict relapse in patients with diffuse large B-cell lymphoma (DLBCL)
MAESTRO-Pool, a means of detecting circulating tumor DNA (ctDNA), could be sensitive and selective enough to help guide treatment decisions. Dana-Farber Cancer Institute investigators, in collaboration with researchers from the Broad Institute, demonstrated in a retrospective clinical study that a novel test for ctDNA was more sensitive and more specific…
Updated Odronextamab Data from Relapsed/Refractory Diffuse
Phase 2 primary analysis results presented in ASH oral session demonstrated a 52% objective response rate (ORR), with 31% achieving a complete response (CR) Results from a Phase 1 expansion cohort showed a 48% ORR and 30% CR in patients who had progressed on CAR-T Additional exploratory data from the…
Metagenomic next-gene sequencing for respiratory infections
Introduction Respiratory tract infections are common and occur frequently. Rapid and accurate microbial detection is essential for timely and appropriate treatment. Traditional microbial detection methods have some limitations such as dependence on morphology, long duration, low sensitivity, and high variability.1,2 Metagenomic next-generation sequencing (mNGS) is a new detection technology characterized…
Cell-Free DNA (cfDNA) Testing Market is set to see Revolutionary growth in decade
“Cell-Free DNA (cfDNA) Testing Market” Research Report 2023-2031 | Provides a thorough Overview of the market’s main Types [Donor-Derived Cell-Free DNA (DdcfDNA), Circulating Cell-Free Tumor DNA (CtDNA), Cell-Free Fetal DNA (NIPT)] and Applications [Hospital, Ambulatory Surgical Centers, Cancer Research Institutes], Including growth factors, market Dynamics, and Competitive Analysis. The most…
Cell-Free DNA (cfDNA) Testing Market Insights, Market Players and Forecast Till 2030
Market Overview and Report Coverage Cell-Free DNA (cfDNA) testing is a non-invasive prenatal testing (NIPT) method used to analyze fragments of DNA that are freely circulating in the bloodstream. This technique is primarily employed to screen for genetic abnormalities in fetuses during pregnancy, providing a safer and more accurate alternative…
Circulating Biomarker for Liquid Biopsy Market is growing rapidly worldwide
Statsndata has published a report on the process of collecting, analyzing and interpreting Circulating Biomarker for Liquid Biopsy Market data. It has published reports on how companies collect, analyze and interpret their market data. This helps businesses better understand the Circulating Biomarker for Liquid Biopsy Market, identify customer needs and…
NeoGenomics to Present New Data at San Antonio Breast Cancer Symposium Highlighting Utility of RaDaR for Therapy Response
FT. MYERS, FL / ACCESSWIRE / December 5, 2023 / NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced new data highlighting its RaDaR� assay for minimal residual disease (MRD) will be presented at the 46th annual San Antonio Breast Cancer Symposium (SABCS). RaDaR data will be…
Can breast milk analysis help diagnose early breast cancer?
How DNA sequencing of breast milk can replace tissue imaging for early diagnosis of breast cancer in pregnant and lactating women Markella Loi | 12/05/2023 | 4 min read | News Approximately 1 in 3,000 women will be diagnosed with breast cancer during pregnancy (PrBC) or postpartum period (PPBC), making…
Anticipating Impactful Data in DLBCL
Suchitra Sundaram, MD, discusses several exciting studies to be presented in diffuse large B-cell lymphoma (DLBCL) at this year’s ASH conference, including the Smart Stop trial assessing lenalidomide, rituximab, tafasitamab, and acalabrutinib as initial therapy to potentially reduce chemoimmunotherapy cycles. Additionally, Dr Sundaram previews a study that explores mosunetuzumab and…
Longitudinal detection of circulating tumor DNA
Analysis of Roche KAPA Target Enrichment kit experimental data obtained on an Illumina sequencing system is most frequently performed using a variety of publicly available, open-source analysis tools. The typical variant calling analysis workflow consists of sequencing read quality assessment, read filtering, mapping against the reference genome, duplicate removal, coverage…
Sequencing Paired Tumor DNA and WBCs Improves ctDNA Tracking and Detects Pathogenic Germline Variants in Localized Colon Cancer
Sequencing Paired Tumor DNA and WBCs Improves ctDNA Tracking and Detects Pathogenic Germline Variants in Localized Colon Cancer | PracticeUpdate …
with Expert Insights and Leading Trends
“Cell-Free DNA (cfDNA) Testing Market” [2024-2031] Research Report offers In-Depth Analysis and Insightful Standpoints | Latest Updated Report | Segmentation categorized into Applications (Hospital, Ambulatory Surgical Centers, Cancer Research Institutes), Types (Donor-Derived Cell-Free DNA (DdcfDNA), Circulating Cell-Free Tumor DNA (CtDNA), Cell-Free Fetal DNA (NIPT)), and Regions. Tailored to benefit stakeholders,…
HPV Tumor DNA May Offer Early Warning of Cervical Cancer at High Risk of Relapse
HPV-positive circulating tumor (ct)DNA after chemoradiation (CRT) for cervical cancer had an independent association with worse outcomes, suggesting potential as a biomarker to guide decision-making, a prospective, multicenter study showed. Patients with detectable HPV ctDNA at the end of CRT had significantly worse 2-year progression-free survival as compared with undetectable…
Volition Presents at the 5th Annual Congress of the International Liquid Biopsy Society
HENDERSON, Nev, Nov. 17, 2023 /PRNewswire/ — VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”), a multi-national epigenetics company, is presenting at the 5th Annual Congress of Liquid Biopsy being held in Madrid, Spain. Lea Payen-Gay, Professor in Toxicology and Biochemistry, University of Lyon I Hospices Civils de Lyon, France and Dr. Jake…
Thieme E-Journals – Onkologische Welt / Abstract
Onkologische Welt 2023; 14(07): 332DOI: 10.1055/a-2120-6734 Liquid Biopsy eröffnet neue Möglichkeiten Reimund Freye 1 Baden-Baden › Author Affiliations Bei Patienten mit diffus großzelligem B-Zell-Lymphom (DLBCL) besitzt zirkulierende Tumor-DNA (ctDNA) im Rahmen einer Liquid Biopsy einen präzisen prognostischen Aussagewert. Prof. Sirpa Leppä, Helsinki (Finnland), erläuterte zahlreiche Vorteile und Anwendungsmöglichkeiten. Mit…
Cell-Free DNA (cfDNA) Testing Market 2023 [Modern Report]
[Latest Report – 110 Pages] Our Latest Report on the global “Cell-Free DNA (cfDNA) Testing Market” 2023 shows a steady and strong upward trend in recent years, and this trend is anticipated to remain favorable through 2030. Our report provides a comprehensive examination of the industry, covering aspects such as…
Circulating cell-free DNA fragmentation is a stepwise and conserved process linked to apoptosis | BMC Biology
DNA fragmentation of apoptotic cells is a two-step process which gives rise to major and minor peaks at different places DNA ladder formation is the most well-known characteristic of apoptosis. Since the 1990s, the HL60 cell line has been regarded as an ideal model for studying cell apoptosis [15]. We therefore took advantage of…
Personalized Treatment Sequencing Is a New Way of Thinking in Breast Cancer
Sara M. Tolaney, MD, MPH, chief of the Division of Breast Oncology and associate director of the Susan F. Smith Center for Women’s Cancers, senior physician at Dana-Farber Cancer Institute, and associate professor of medicine at Harvard Medical School, all in Boston, Massachusett In a rapidly evolving field, new strides…
Solved Please give me the answer: 3. Diffuse large B cell
Please give me the answer: 3. Diffuse large B cell lymphoma (DLBCL) represents the most common subtype of non-Hodgkin lymphoma (NHL). The following questions are based on the Circulating tumor DNA: clinical roles in diffuse large B cell lymphoma. Ann Hematol. 2019;98:255-269. PMID: 30368587. (i) What are the current strategies…
New blood test may help detect disease earlier
Share on PinterestExperts say a blood test for lung cancer would help with earlier diagnosis. Lourdes Balduque/Getty Images Lung cancer is the leading cause of cancer-related deaths globally. Most lung cancer cases are not diagnosed until the advanced stage, lowering a person’s 5-year survival rate. Currently, the only screening available…
tumor fraction estimation and fragment size plot using sWGS data
tumor fraction estimation and fragment size plot using sWGS data 1 Hi all, We have sequenced several cancer patients’ ctDNA, and get some sWGS data. In order to compare the data before and after treatments, we want to focus on the fragments and tumor fraction. Besides ichorCNA, is there any…
Detection of the Uveal Melanoma-Associated Mutation GNAQ Q209P from Liquid Biopsy Using CRISPR/Cas12a Technology
Uveal melanoma (UM) is a rare ocular tumor characterized by high metastasis risk and poor prognosis. The in-depth characterization of UM’s molecular profile is critical for better disease classification and prognosis. Furthermore, the development of detection tools to monitor UM evolution upon treatment is of great interest for designing optimal…
Illumina launches advanced liquid biopsy assay to enable comprehensive genomic profiling of solid tumors
TSO 500 ctDNA Version 2 delivers faster turnaround time, greater analytical sensitivity, more streamlined workflow, further enabling precision medicine. SAN DIEGO, Nov. 1, 2023 /PRNewswire/ — Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced a new generation…
What does the future hold?
In this interview, Adanma Ayanambakkam, MD, discusses the current state of treatment of advanced bladder cancer, including the need for predictive and prognostic markers for immune therapy as well as the potential showed by circulating tumor DNA (ctDNA). Ayanambakkam is an assistant professor of medicine in the section of hematology/oncology…
The future of cancer is very personal
On this planet of more than 7.8 billion people, there’s no one quite like you. Genetically speaking, that is. That’s why the future of cancer care is personal – tailored to fit the distinct variations in your genetic blueprint. Until now, cancer treatments have been largely reliant on surgery, or…
Future of cancer is very personal
On this planet of more than 7.8 billion people, there’s no one quite like you. Genetically speaking, that is. That’s why the future of cancer care is personal – tailored to fit the distinct variations in your genetic blueprint. Until now, cancer treatments have been largely reliant on surgery, or…
Personalis start early access program for cancer detection blood test
NeXT Personal Dx has a specificity exceeding 99.9% and can detect down to 1×10-⁶ tumour fraction. Credit: ArtemisDiana / Shutterstock. Personalis has launched the Early Access Program for NeXT Personal Dx, a liquid biopsy laboratory-developed test for detecting molecular residual disease (MRD) and recurrence in cancer. NeXT Personal Dx is…
QIAGEN and Myriad Genetics partner to advance companion diagnostics development for cancer
Partnership covers development of lab-developed and distributable kit-based companion diagnostic tests // Combined strengths in assay development, clinical testing, and regulatory approvals offers pharma partners comprehensive global companion diagnostic solutions based on PCR, digital PCR (using the QIAcuity system), and NGS // Future projects may include advanced analysis and accessibility…
Phase 3 Trial Supports Amivantamab Plus Lazertinib Over Osimertinib in Advanced EGFR+ NSCLC
Phase 3 Trial Supports Amivantamab Plus Lazertinib Over Osimertinib in Advanced EGFR+ NSCLC In the frontline setting, amivantamab-vmjw (Rybrevant) and lazertinib (Leclaza) outperformed osimertinib (Tagrisso) alone in the phase 3 MARIPOSA trial (NCT04487080) that were presented at the 2023 ESMO Congress.1 Patients with advanced non–small cell lung cancer (NSCLC) harboring classical EGFR sensitizing mutations, who received…
From innovation to impact: Harnessing Real-World data to generate Real-World insights that accelerate the impact of precision medicine in Breast Cancer Treatment
Breast cancer affects millions of people worldwide. In 2020, 2.3 million women were diagnosed with breast cancer globally (1). In the UK, it is the most common cancer among women, with over 55,000 new cases diagnosed each year (2). Around 0.5-1% of breast cancers occur in men (1). In the…
Liquid Biopsy Provides Earlier Detection of an Inherited Cancer
Credit: AlexRaths/iStock Researchers at the Hospital for Sick Children (SickKids), the Ontario Institute for Cancer Research (OICR), and the University Health Network (UHN) have developed a liquid biopsy that an initial study has shown provides earlier detection cancer in individuals with Li-Fraumeni syndrome (LFS) than existing methods. LFS is hereditary…
Phase 3 Study Results Show Tebentafusp Provides Long-Term Survival Benefit in Patients With Metastatic Uveal Melanoma
Data from the randomized phase 3 KIMMTRAK study (NCT03070392) show that tebentafusp-tebn (Kimmtrak; Immunocore) continues to provide long-term survival benefit in patients with previously untreated HLA-A*02:01+ metastatic uveal melanoma (mUM). Tebentafusp is a bispecific (gp100 x CD3) immune mobilizing monoclonal T-cell receptor against cancer that is approved for treatment in…
Liquid Biopsy Detects Cancer Earlier in Patients with Inherited Disorder
Researchers at the Hospital for Sick Children (SickKids), the Ontario Institute for Cancer Research (OICR), and the University Health Network (UHN) have developed a method for analyzing blood samples that an initial study has shown can detect cancer in individuals with Li-Fraumeni syndrome (LFS) earlier than existing surveillance methods. LFS…
Breakthrough Liquid Biopsy Blood Test Method Enables Accurate, Rapid, Low-Cost Detection of Cancer – molecular-diagnostics
Image: A new cancer detection method may pave the way for undiscovered biomarkers (Photo courtesy of VolitionRx) In the early stages of cancer, detecting circulating tumor DNA (ctDNA) in a blood sample is a challenging task. This is because ctDNA may only make up a minuscule 0.01% of the total…
Volition Presents Breakthrough Liquid Biopsy Blood Test Method for Early-stage Cancer
HENDERSON, Nev., Oct. 23, 2023 /PRNewswire/ —VolitionRX Limited (NYSE AMERICAN: VNRX) (“Volition”), a multi-national epigenetics company, has unveiled what it believes to be an entirely new cancer detection method at ESMO 2023¹, the annual congress of the European Society for Medical Oncology. In early-stage…
Immunocore presents three-year overall survival data from the KIMMTRAK Phase 3 trial
This section is Partnership Content supplied The content in this section is supplied by GlobeNewswire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by GlobeNewswire Breadcrumb Trail Links GlobeNewswire Author of the article: Published Oct 21, 2023 • 9 minute…
Personalis, Inc. Announces the Presentation of Initial Findings from Its Work with the Tracerx Lung Cancer Study -October 21, 2023 at 04:25 am EDT
Personalis, Inc. announced the presentation of initial findings from its work with the TRACERx lung cancer study, marking a substantial advancement in lung cancer circulating tumor DNA (ctDNA) detection and management. Thealis NeXT Personal cancer assay, created to detect and monitor residual and recurrent disease (MRD), demonstrated significantly improved detection…
Circulating Tumor DNA from Ascites as an alternative to tumor sampling for genomic profiling in ovarian cancer patients | Biomarker Research
To the editor, Genomic testing is crucial for the management of ovarian cancer (OC). Approximately 25% of high-grade OC have germline or somatic BRCA1 or BRCA2 mutations [1]. 50% of high-grade OC are homologous recombination deficient (HRD). HRD is defined by the detection of a BRCA1 or BRCA2 mutation, or…
Predicine announces six studies showcasing MRD and liquid
HAYWARD, Calif., Oct. 17, 2023 (GLOBE NEWSWIRE) — Predicine, a pioneer in the liquid biopsy, announce its participation in the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain. The company will present six compelling poster studies, unveiling the future of liquid biopsy solutions. These poster presentations will…
AMP publishes best-practice recommendations for ctDNA assays
The Association for Molecular Pathology (AMP) has published its best-practice recommendations for validating, reporting, and publishing clinical circulating tumor DNA (ctDNA) assays. The recommendations, published online in the Journal of Molecular Diagnostics, were developed by AMP’s Clinical Practice Committee’s Liquid Biopsy Working Group, with representation from the American Society of…
Cell-Free DNA (cfDNA) Testing Market Size Research Report [2023-2030]
“Cell-Free DNA (cfDNA) Testing Market” Research Report Provides Detailed Historical Analysis of Global market for Cell-Free DNA (cfDNA) Testing from 2017 2022, and provides Extensive Market Forecasts From 2023 2030 By Applications (Hospital, Ambulatory Surgical Centers, Cancer Research Institutes),Types (Donor-Derived Cell-Free DNA (DdcfDNA), Circulating Cell-Free Tumor DNA (CtDNA), Cell-Free Fetal…
Introduction to cfDNA; The Difference Between cfDNA and ctDNA
cfDNA is a DNA fragment released by various cells into the blood or other body fluids. cfDNA can serve as a biomarker for various diseases, especially cancer, reflecting the genomic variation and gene expression of tumor cells. cfDNA analysis has become a promising method for cancer diagnosis, treatment selection, and…
The landscape of cell-free mitochondrial DNA in liquid biopsy for cancer detection | Genome Biology
Dawson SJ, Tsui DWY, Murtaza M, Biggs H, Rueda OM, Chin SF, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med. 2013;368:1199–209. Massachusetts Medical Society. Article CAS PubMed Google Scholar van der Pol Y, Mouliere F. Toward the early detection of cancer by…
Cell-Free DNA (cfDNA) Testing Market 2023
Global Cell-Free DNA (cfDNA) Testing Market Size 2023-2030 – Global Cell-Free DNA (cfDNA) Testing Market 2023-2030 Adaptive Research Reports encompass a comprehensive analysis that includes categorizing Types (Donor-Derived Cell-Free DNA (DdcfDNA), Circulating Cell-Free Tumor DNA (CtDNA), Cell-Free Fetal DNA (NIPT)) and Applications (Hospital, Ambulatory Surgical Centers, Cancer Research Institutes), delving…
Liquid Biopsy ctDNA Could Serve as Early Marker of Immunotherapy Response
Results from the first stage of a Phase II clinical trial suggest that measuring circulating tumor DNA (ctDNA) captured in blood-based liquid biopsies may help to identify those advanced non-small cell lung cancer (NSCLC) patients undergoing immunotherapy who could benefit from treatment with additional drugs. Data from this first stage…
ASCO Reading Room | Circulating Tumor DNA: Up-and-Coming in Early-Stage NSCLC, On Deck in Advanced Disease
A 2020 Nature Cancer study found that patients with advanced non-small cell lung cancer (NSCLC) who had undetectable circulating tumor (ct)DNA after chemoradiotherapy “had excellent outcomes whether or not they received consolidation immune checkpoint inhibition (CICI) … the ctDNA response pattern early during CICI identified patients responding to consolidation therapy.”…
Circulating Biomarker for Liquid Biopsy Market Analysis to 2029
Statsndata published a report on the process of collecting, analyzing and interpreting Circulating Biomarker for Liquid Biopsy Market data. New published reports on companies to collect, analyze and interpret Circulating Biomarker for Liquid Biopsy market data. This not only accelerates individual business growth but also contributes to the overall progress…
PDS0101 and CRT Displays Encouraging Early Data in Cervical Cancer
gynecologic cancer, cervical cancer: © tom – stock.adobe.com The combination of PDS0101 with standard-of-care (SOC) chemoradiotherapy (CRT) was associated with a rapid decline in human papillomavirus (HPV) circulating cell-free DNA (cfHPV-DNA), suggesting a potential predictive biomarker of treatment response, according to findings from the phase 2 IMMUNOCERV clinical trial (NCT04580771).1…
PDS Biotech – PDS Biotech Announces PDS0101 Combined with Chemoradiotherapy Associated with Rapid Decline in Circulating Tumor DNA (ctDNA/cfDNA)
Study evaluated levels of circulating cell-free HPV DNA (cfDNA) in patients with locally advanced cervical cancer in the IMMUNOCERV Phase 2 clinical trial and patients receiving standard of care (SOC) treatment Patients treated with PDS0101 had greater clearance of cfDNA as compared to those treated with SOC (at week 5,…
ctDNA Pushes Its Prognostic Role in Large Cell Lymphomas
Large cell lymphomas are curable, but aggressive. Despite that, some 30% to 40% of patients with diffuse large B-cell lymphoma (DLBCL) will develop relapsing/refractory disease.1 To ensure a cure, physicians typically use CT and positron emission tomography-computedtomography (PET-CT) scans to look for signs of minimum residual disease (MRD) when treatment…
Identifying ESR1 Mutations to Determine Resistance in HR+ Metastatic Breast Cancer
The global disease burden of breast cancer (BC) is a serious health concern worldwide, especially among women. Globally, about 2.3 million women were diagnosed with BC in 2020, and there were 685,000 deaths from BC.1 Various BC subtypes have been identified based on the expression of genes encoding hormone receptors…
Predicting tumour content of liquid biopsies from cell-free DNA | BMC Bioinformatics
Forshew T, Murtaza M, Parkinson C, Gale D, Tsui DWY, Kaper F, et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med. 2012;4(136):136ra68. Article PubMed Google Scholar Newman AM, Bratman SV, To J, Wynne JF, Eclov NCW, Modlin LA, et al….
Cell-Free DNA (cfDNA) Testing Market Size, Trends Report 2023-2031
“Cell-Free DNA (cfDNA) Testing Market” Research Report Revealing a Comprehensive Analysis of Industry Trends, Growth, and Opportunities By Types (Donor-Derived Cell-Free DNA (DdcfDNA), Circulating Cell-Free Tumor DNA (CtDNA), Cell-Free Fetal DNA (NIPT)), By Application (Hospital, Ambulatory Surgical Centers, Cancer Research Institutes), By Regional Outlook and Forecast, 2023 – 2031″ Browse…
BillionToOne hiring Director of Bioinformatics, Prenatal in Menlo Park, California, United States
Do you want to join one of the fastest-growing molecular diagnostics startups and develop products that can affect the lives of millions? BillionToOne, ranked at the top 5% of Y Combinator companies with $250M+ in funding from prominent VC firms, has developed a DNA molecular counter that increases cfDNA diagnostic…
‘AI will play major role in drug discovery, development’: Dr Jame Abraham
There are theories about why Hippocrates, the father of medicine, named a cluster of abnormal cells karkinos (Greek for crab). Was it because the tumour felt hard as a rock, reminding him of the crab’s shell? Or, was it because of the stubborn nature of the disease, quite like how…
2023 Cell-Free DNA (cfDNA) Testing Market Growth Report Size | consumption by Regional data, Business Insights 2031 | 89 Pages
2023 Cell-Free DNA (cfDNA) Testing Market Overview: Insights on [ Hospital, Ambulatory Surgical Centers, Cancer Research Institutes ] and [ Donor-Derived Cell-Free DNA (DdcfDNA), Circulating Cell-Free Tumor DNA (CtDNA), Cell-Free Fetal DNA (NIPT) ], Regional Analysis, and Impact of COVID-19. Includes 89-Page Detailed Report with Tables and Charts. The Global…
Breast Cancer Detected in Breast Milk Earlier Than in Plasma
Researchers say they have detected breast cancer in circulating tumor DNA (ctDNA) from breast milk, and breast milk may allow for earlier cancer detection than plasma. These results “open up the potential” to use breast milk as a new source for liquid biopsy for breast cancer detection, according to the…
Efforts Are Underway to Refine Prognostic Value of ctDNA to Guide Adjuvant Therapy in CRC
Circulating tumor DNA(ctDNA) status at the time of postoperative minimal residual disease (MRD) is a prognostic factor of recurrence for patients with radically resected stage II to IV colorectal cancer (CRC). Standard management calls for adjuvant chemotherapy for all patients following surgical resection; however, investi- gators have sought to refine…
Cell-Free DNA (cfDNA) Testing Market Share, Size and Forecast to 2030 | Agilent Technology, Allenex, Biocept
PRESS RELEASE Published September 20, 2023 Introduction: “Cell-Free DNA (cfDNA) Testing Market” New Research Insight Report 2023 | Spread Across 110 Pages Report which provides an in-depth analysis Based on Regions, Applications (Hospital, Ambulatory Surgical Centers, Cancer Research Institutes), and Types (Donor-Derived Cell-Free DNA (DdcfDNA), Circulating Cell-Free Tumor DNA (CtDNA),…
Cell-Free DNA (cfDNA) Testing Market 2023-2031 with Industry Analysis
[110 Pages Report] | Cell-Free DNA (cfDNA) Testing Market is anticipates experiencing substantial expansion in the upcoming years by it’s Application [Hospital, Ambulatory Surgical Centers, Cancer Research Institutes], & by Type [Donor-Derived Cell-Free DNA (DdcfDNA), Circulating Cell-Free Tumor DNA (CtDNA), Cell-Free Fetal DNA (NIPT)] Region Forecast to 2031. The report…
Myriad Genetics, Memorial Sloan Kettering collaborate on MRD testing for breast cancer
Myriad Genetics is collaborating with Memorial Sloan Kettering Cancer Center (MSK) to study the use of Myriad’s minimal residual disease (MRD) testing platform in predicting breast cancer treatment response. The platform is a tumor-informed high-definition assay that monitors circulating tumor DNA (ctDNA) levels via whole-genome sequencing. The partners will be…
Cell-Free DNA (cfDNA) Testing Market Trends Research Report [2023-2030] | 110 Pages
360 Research Reports has published a new report titled as “Cell-Free DNA (cfDNA) Testing Market” by End User (Hospital, Ambulatory Surgical Centers, Cancer Research Institutes), Types (TYPE1), Region and Global Forecast to 2023-2030. This Exclusive Data Report also presents qualitative and quantitative perspectives on SWOT and PESTLE analysis based on…
Breast milk may help in early detection of breast cancer
– Advertisement – London– In a significant breakthrough, Spanish researchers have shown for the first time that breast milk from breast cancer patients contains tumour DNA, and may help in early detection of the most common type of cancer affecting women worldwide. The tumour DNA, known as circulating tumour DNA…
Next-Generation Sequencing and Lung Cancer Treatment
is the second most common form of cancer and the leading cause of cancer deaths in both men and women in the United States. Advanced-stage lung cancer is usually treated with chemotherapy, a combination of chemo-immunotherapy, immunotherapy, or a targeted agent. Targeted drugs are recommended if your doctor detects the…
FLAURA Data Provides Insight on Sequencing Therapy for EGFR+ NSCLC
Martin F. Dietrich, MD, PhD Hematologist/Medical Oncologist Florida Cancer Specialists & Research Institute Assistant Professor, Internal Medicine University of Central Florida Orlando, FL Targeted OncologyTM: What was the significance of the FLAURA study (NCT02296125) in the EGFR-mutated non–small cell lung cancer (NSCLC) setting? DIETRICH: The current standard-of-care [comes from] the…
Genomic profiling of post-transplant lymphoproliferative disorders using cell-free DNA | Journal of Hematology & Oncology
The median age of the patients was 55 years (range 13–74). Median time between SOT and PTLD was 95 months (range 2–338). Most patients had stage IV disease (n = 13, 76%) with a median metabolic tumor volume (MTV) of 302 mL (range 5–2070 mL). Lactate dehydrogenase (LDH) levels ranged from 210 to 5068 (Additional file…
Cell-Free DNA (cfDNA) Testing Market Trends 2023-2030 | 97 Pages Report
Global 97 Pages Latest Report on “Cell-Free DNA (cfDNA) Testing Market” research report provides the latest information about prominent global key players (Agilent Technology , Allenex , Biocept , Biodesix , CareDx , Guardant Health , Illumania , Invited , Natera , Quest Diagnostics , Roche Holdings , Etc.), companies…
ctDNA May Play Role in Large Cell Lymphoma Detection
Currently, CT/PET scans are primarily used for staging, response assessment, and surveillance, according to Mark J. Roschewski, MD. The use of circulating tumor DNA (ctDNA) may supplement imaging scans, effectively aiding in detecting active large cell lymphoma in patients near the end of treatment, according to Mark J. Roschewski, MD…
Cell-Free DNA (cfDNA) Testing Market Size, Exclusive Data Report Forecast 2028
Our in-depth study of the Global Cell-Free DNA (cfDNA) Testing Market delivers a thorough understanding of its ever-changing dynamics. Our investigation encompasses precise data, yearly and quarterly market valuations, competitor evaluations, and market projections. We explore significant market facets such as market share, growth pace, dimensions, and regional progressions. The…
Cell-Free DNA (cfDNA) Testing Market Share Report 2023-2030 | 110 Pages Report
Introduction: “Cell-Free DNA (cfDNA) Testing Market” Insights Report 2023 | Spread Across 110 Pages Report which provides an in-depth analysis Based on Regions, Applications (Hospital, Ambulatory Surgical Centers, Cancer Research Institutes), and Types (Donor-Derived Cell-Free DNA (DdcfDNA), Circulating Cell-Free Tumor DNA (CtDNA), Cell-Free Fetal DNA (NIPT)). The report presents the…
Acutis Biosciences’ CSO Dr. Abdel Halim Co-Authors a Precision Medicine Study in NEJM
Highlights the value of companion diagnostics in the drug industry and the effectiveness of ctDNA testing in blood samples instead of invasive tumor biopsies for patient screening in clinical trials, The assay demonstrated ctDNA liquid biopsy can be an alternative or complement to tissue samples and decrease sample failure rate, Laboratory…
Cell-Free DNA (cfDNA) Testing Market Research Report on Regional Size and Status 2023-2030
The Cell-Free DNA (cfDNA) Testing Market Insights of 2023 is an extensive and comprehensive report that provides a complete analysis of the market’s size, shares, revenues, various segments, drivers, trends, growth, and development. The report also highlights the limiting factors and regional industrial presence that may affect the market’s growth…
Lucence Presses Forward With Favorable Results From Liquid Biopsy Lung Cancer Studies
This article has been updated to provide greater clarity on the comparisons made in the Liquik study. NEW YORK – Precision oncology company Lucence plans to present interim results from the ongoing Liquik liquid biopsy lung cancer study and data pointing toward the potential benefits of cell-free RNA testing for earlier…
Brigatinib Not Superior to Alectinib in ALK-Positive NSCLC
3D illustration of lung tumor © SciePro – stock.adobe.com Progression-free survival (PFS) results with brigatinib (Alunbrig) were not superior to that observed with alectinib (Alecensa) in crizotinib (Xalkori)-pretreated patients with ALK-positive non–small cell lung cancer (NSCLC), according to findings from the phase 3 ALTA-3 study (NCT03596866).1 Though brigatinib was not…
Targeted DNA Sequencing Market Forecast from 2023 – 2030 Growing at a CAGR of 9% with Key Players and Market Analysis
The “Targeted DNA Sequencing Market” report draws on various inferences to analyze the challenges within the industry. The final draught highlights the industry’s typical problems as well as the businesses facing them. This report is of 143 pages. The Targeted DNA Sequencing market is expected to grow annually by 9%…
Cell-free DNA chromosome copy number variations predict outcomes in plasma cell myeloma
Testing for measurable residual disease (MRD) in persons with plasma cell myeloma (PCM) after therapy correlates with therapy outcomes including progression-free survival (PFS) and survival (reviewed in refs. [1, 2]). Most MRD-testing in this setting uses multi-parameter flow cytometry (MPFC) but prediction accuracy is imperfect with C-statistics of only about…
Building A Comprehensive Whole-Genome Cancer Monitoring Platform
C2i Genomics is the first company to develop the most comprehensive whole-genome monitoring of cancer recurrence and progression by analyzing subtle changes in the pattern of the tumor’s DNA. Pulse 2.0 interviewed C2i Genomics’ co-founder and CEO Ezra Sofer to learn more. Ezra Sofer’s Background Sofer focuses on leading the…
Geneos Therapeutics’ Groundbreaking Cancer Vaccine Trial Yields Remarkable Results: Complete Response Achieved in 8 out of 34 Patients with Advanced Liver Cancer
PLYMOUTH MEETING, PA — Geneos Therapeutics, a clinical-stage biotherapeutics company, recenlty announced updated data from GT-30, an ongoing single-arm open-label multi-center Phase 1b/2a study in second-line advanced hepatocellular carcinoma (HCC). Previously, Geneos reported three patients to have achieved a complete response (CR) and a fourth patient to be cancer-free, whose…
The Impact of Molecular Diagnostics on Disease Detection and Treatment
Molecular diagnostics revolutionises disease detection with accurate, rapid tools like point-of-care tests and liquid biopsies. Its potential to transform healthcare and save lives is promising. FREMONT, CA: The field of molecular diagnostics has experienced remarkable advancements, leading to a fundamental transformation in the methods used to identify and diagnose diseases. Traditional…
Analyzing Trends and Projected Outlook for 2023-2030
“Cell-Free DNA (cfDNA) Testing Market” Research Report 2023 includes detailed market segmentation based on Regions, Applications (Hospital, Ambulatory Surgical Centers, Cancer Research Institutes), and Types (Donor-Derived Cell-Free DNA (DdcfDNA), Circulating Cell-Free Tumor DNA (CtDNA), Cell-Free Fetal DNA (NIPT)). The report presents the research and analysis provided within the Cell-Free DNA…
Using cfDNA and ctDNA as Oncologic Markers: A Path to Clinical Validation
Abstract The detection of circulating tumor DNA (ctDNA) in liquid biopsy samples as an oncological marker is being used in clinical trials at every step of clinical management. As ctDNA-based liquid biopsy kits are developed and used in clinics, companies work towards increased convenience, accuracy, and cost over solid biopsies…
Genomics Market Size, Share, Growth, Outlook 2023-2030
PRESS RELEASE Published August 22, 2023 “Genomics Market – DataM Intelligence” Genomics Market is estimated to grow at a CAGR of 18.7% during the forecast period 2023-2030 Market Overview: The branch of biology known as genomics focuses on understanding an organism’s entire gene or genetic makeup (DNA). It entails deciphering…